Investigating the contents of atherosclerotic plaques using novel imaging techniques including PET/MRI

The DTP FDG-PET-MRI study for assessment of inflammation, lipid-rich necrotic core and intraplaque hemorrhage in the atherosclerotic plaque

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

ISRCTN

Registry ID

ISRCTN30673005

Enrollment

Registered

2021-01-05

Start date

2018-04-01

Completion date

Unknown

Last updated

2021-08-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Atherosclerotic plaque composition in patients with high-grade carotid stenosis Circulatory System Occlusion and stenosis of carotid artery

Interventions

In patients with high-grade carotid stenosis the extent of lipid-rich necrotic core and intraplaque hemorrhage is quantified from fat and R2* maps acquired with a previously validated four-point Dixon

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: =50% carotid stenosis (corresponds to a Doppler flow velocity =1.3 m/sec at a Doppler angle of 50-60°)

Exclusion criteria

Exclusion criteria: 1. Previous carotid endarterectomy 2. Carotid occlusion 3. Diabetes mellitus 4. Renal failure (GFR <45 ml/min/1.73m²) 5. Inflammatory diseases including malignancies, immunologic disorders 6. Treatment with immunosuppressive/anti-inflammatory agents

Design outcomes

Primary

Measure	Time frame
1. Lipid-rich necrotic cores (fat) and intraplaque hemorrhage (blood) in atherosclerotic plaques are measured using a novel and thoroughly validated quantitative MRI (qMRI) technique at study baseline 2. Inflammation measured using 18F-fluoro-deoxyglucose (18F- FDG) uptake quantified in the same plaques on images acquired using a simultaneous whole-body PET/MRI scanner at study baseline, as close in time to the qMRI assessment as possible	—

Measure

Time frame

1. Lipid-rich necrotic cores (fat) and intraplaque hemorrhage (blood) in atherosclerotic plaques are measured using a novel and thoroughly validated quantitative MRI (qMRI) technique at study baseline 2. Inflammation measured using 18F-fluoro-deoxyglucose (18F- FDG) uptake quantified in the same plaques on images acquired using a simultaneous whole-body PET/MRI scanner at study baseline, as close in time to the qMRI assessment as possible

—

Secondary

Measure	Time frame
There are no secondary outcome measures	—

Countries

Sweden

Contacts

Public ContactElin Good

elin.good@liu.se+46 (0)10 103 00 00

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 14, 2026